Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 8Withdrawn 3Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms by Site 2Neoplasms 2Multiple Myeloma 2Glioblastoma 2Digestive System Neoplasms 2Digestive System Diseases 2Thrombocythemia, Essential 1Sarcoma 1Rectal Diseases 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Diseases 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Leukemia, Myeloid, Acute 1Intestinal Neoplasms 1Intestinal Diseases 1Gliosarcoma 1Glioma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Colorectal Neoplasms 1Colonic Diseases 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Ascorbic Acid × Clear all
NCT00590603 2014-01-08

AAV

Duke University

Phase 1 Terminated
25 enrolled
Plasma cell

Multiple Myeloma

NCT00227682 2012-05-28

Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

OHSU Knight Cancer Institute

Phase 2 Terminated
2 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡